Daxor Corporation (DXR) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Daxor Corporation (DXR:NASDAQ), powered by AI.

Current Price
$10.00
P/E Ratio
5.4
Market Cap
50M
Sector
Healthcare
What is the Daxor Corporation stock price forecast?

Daxor Corporation is currently trading at $10.00. View real-time AI analysis on Alpha Lenz.

What is Daxor Corporation insider trading activity?

View the latest insider trading data for Daxor Corporation on Alpha Lenz.

What is Daxor Corporation's P/E ratio?

Daxor Corporation's P/E ratio is 5.4.

Daxor Corporation

NASDAQ · DXR
$10.00+0.33(+3.41%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Daxor Corporation's future dividend policy...
Alpha Chat Insight

Daxor Corporation trades at a P/E of 5.4 (undervalued) with strong ROE of 22.5%. 3Y revenue CAGR of 17.8% highlights clear growth momentum.

Ask for details

Company Overview

Daxor Corporation is a medical instrumentation and biotechnology company focused on providing innovative solutions for blood volume analysis. Its primary product, the Blood Volume Analyzer (BVA-100), is a diagnostic tool used to precisely quantify the blood volume status of patients. This capability assists healthcare professionals in making informed decisions regarding fluid management, which is critical in treating conditions such as heart failure, hypertension, and trauma. Daxor's technology plays a vital role in enhancing patient outcomes and optimizing treatment in both surgical and intensive care settings. The company's contributions are significant in the healthcare sector, where accurate patient monitoring can have life-saving implications. Headquartered in New York, Daxor also actively engages in ongoing research and development to expand the applications of its patented technology, aiming to address unmet needs in patient care. Within the financial market, Daxor represents a niche player in the biomedical devices and diagnostics industry, drawing interest from investors who focus on innovative healthcare technologies. Its role in enhancing diagnostic accuracy underscores its importance in the medical field."}

CEOMr. Michael Richard Feldschuh
SectorHealthcare
IndustryMedical Instruments & Supplies
0

Company Statistics

FY 2025

Profile

$49.85MMarket Cap
$10.30MRevenue
0.00Shares Out
0Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
89.00%Pre-Tax
89.00%Net

Valuation

5.44P/E
1.09P/B
4.84EV/Sales
N/AEV/EBITDA
87.32P/FCF

Growth (CAGR)

17.75%Rev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
20.98%Net Inc 3Yr
N/ANet Inc 5Yr

Returns

22.19%ROA
22.45%ROE
N/AROIC

Financial Health

N/ACash & Cash Equivalents
N/ANet Debt
0.27%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Daxor Corporation (ticker: DXR) is a company listed on NASDAQ in the Healthcare sector (Medical Instruments & Supplies). Market cap is $50M.

The current price is $10 with a P/E ratio of 5.44x and P/B of 1.09x.

ROE is 22.45%. Annual revenue is $10M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Daxor Corporation (DXR) Stock Forecast 2026 $10.00 — Price, Financials & Analyst Targets | Alpha Lenz